The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial

Biber et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.07.003 (results 2/12/21), NCT04429711

Feb 2021

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.

Lower risk for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 109 treatments. c19ivm.org

Double blind RCT for mild-moderate COVID-19 outpatients in Israel showing significantly faster reduction in viral load with treatment, and lower hospitalization with treatment. The one treatment hospitalization was a few hours after treatment and the patient improved and was discharged quickly. Authors also examine culture viability on days 2-6, with 13% positive in the ivermectin group vs. 48% in the control group. There were no safety issues. Ivermectin was taken one hour before a meal. Sheba IRB-7156/20.

This is the 17th of 52 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000021.

This is the 37th of 105 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 774 quintillion).

Important missing comments or errors? Let us know.

risk of hospitalization, 70.2% lower, RR 0.30, p = 0.34, treatment 1 of 47 (2.1%), control 3 of 42 (7.1%), NNT 20.

risk of no viral clearance, 61.6% lower, RR 0.38, p = 0.02, treatment 8 of 47 (17.0%), control 17 of 42 (40.5%), NNT 4.3, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, Ct>30, multivariable, day 8.

risk of no viral clearance, 39.0% lower, RR 0.61, p = 0.09, treatment 13 of 47 (27.7%), control 21 of 42 (50.0%), NNT 4.5, adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, Ct>30, multivariable, day 6, primary outcome.

risk of no viral clearance, 73.0% lower, RR 0.27, p = 0.008, treatment 3 of 23 (13.0%), control 14 of 29 (48.3%), NNT 2.8, culture viability.

risk of no viral clearance, 70.2% lower, RR 0.30, p = 0.14, treatment 2 of 47 (4.3%), control 6 of 42 (14.3%), NNT 10.0, non-infectious samples (Ct>30 or non-viable culture), day 10.

risk of no viral clearance, 82.1% lower, RR 0.18, p = 0.01, treatment 2 of 47 (4.3%), control 10 of 42 (23.8%), NNT 5.1, non-infectious samples (Ct>30 or non-viable culture), day 8.

risk of no viral clearance, 75.6% lower, RR 0.24, p = 0.02, treatment 3 of 47 (6.4%), control 11 of 42 (26.2%), NNT 5.0, non-infectious samples (Ct>30 or non-viable culture), day 6.

risk of no viral clearance, 65.1% lower, RR 0.35, p = 0.05, treatment 4 of 28 (14.3%), control 9 of 22 (40.9%), NNT 3.8, non-infectious samples (Ct>30 or non-viable culture), day 4.

risk of no viral clearance, 51.9% lower, RR 0.48, p = 0.08, treatment 7 of 47 (14.9%), control 13 of 42 (31.0%), NNT 6.2, Ct>30, day 10.

risk of no viral clearance, 57.9% lower, RR 0.42, p = 0.02, treatment 8 of 47 (17.0%), control 17 of 42 (40.5%), NNT 4.3, Ct>30, day 8.

risk of no viral clearance, 44.7% lower, RR 0.55, p = 0.049, treatment 13 of 47 (27.7%), control 21 of 42 (50.0%), NNT 4.5, Ct>30, day 6.

risk of no viral clearance, 31.9% lower, RR 0.68, p = 0.16, treatment 13 of 28 (46.4%), control 15 of 22 (68.2%), NNT 4.6, Ct>30, day 4.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Biber et al., 12 Feb 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Israel, peer-reviewed, 10 authors, study period 12 May, 2020 - 31 October, 2020, average treatment delay 4.0 days, dosage 12mg days 1-3, 15mg for patients ≥70kg, trial NCT04429711 (history). Contact: elischwa@tauex.tau.ac.il.

This Paper Ivermectin All

The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial

Asaf Biber, Geva Harmelin, Dana Lev, Li Ram, Amit Shaham, Ital Nemet, Limor Kliker, Oran Erster, Michal Mandelboim, Eli Schwartz

International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.07.003

The effect of ivermectin on the viral load and culture viability in early treatment of non-hospitalized patients with mild COVID-19 -A double-blind, randomized placebo-controlled trial,

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

References

Basso, Aita, Navaglia, Franchin, Fioretto et al., SARS-CoV-2 RNA identification in nasopharyngeal swabs: issues in pre-analytics, Clin Chem Lab Med, doi:10.1515/cclm-2020-0749

Biancofiore, Mirijello, Puteo, Di Viesti, Labonia et al., Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: A retrospective case-control study, Journal of Medical Virology, doi:10.1002/jmv.27598

Bray, Rayner, Noël, Jans, Wagstaff, Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res, doi:10.1016/j.antiviral.2020.104805

Brown, Chand, Andrews, Auckland, Beshir, Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England, J Infect, doi:10.1016/j.jinf.2020.06.069

Bryant, Lawrie, Dowswell, Fordham, Mitchell et al., Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, Am J Ther, doi:10.1097/MJT.0000000000001402

Bullard, Dust, Funk, Strong, Alexander et al., Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples, Clin Infect Dis, doi:10.1093/cid/ciaa638

Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787

Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?, Antiviral Res, doi:10.1016/j.antiviral.2012.06.008

Carroll, Mcnamara, Comparison and correlation of commercial SARS-CoV-2 real-time-PCR assays, Ireland, Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, doi:10.2807/1560-7917.ES.2021.26.6.2002079

Choudhury, Das, Patra, Bhattacharya, Ghosh et al., Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach, Future Virology, doi:10.2217/fvl-2020-0342

Eweas, Alhossary, As, Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2, Frontiers in Microbiology, doi:10.3389/fmicb.2020.592908

Fischer, Eron, Holman, Cohen, Fang et al., A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med, doi:10.1126/scitranslmed.abl7430

Gilad, Oran, Itai, Eli, Evaluation of the relationship between quantitative PCR results and cell culturing of SARS2-CoV with respect to symptoms onset and Viral load -a systematic review, MedRxiv, doi:10.1101/2021.08.23.21262162

Götz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep, doi:10.1038/srep23138

Hill, Mirchandani, Pilkington, Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud, Open Forum Infect Dis, doi:10.1093/ofid/ofab645

Laing, Devaney, Ivermectin -Old Drug, New Tricks?, Trends Parasitol, doi:10.1016/j.pt.2017.02.004

Lefferts, Blake, Bruden, Hagen, Hodges et al., Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7108a3

Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/S0140-6736(20)30628-0

Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis, Journal of Pharmacy & Pharmaceutical Sciences : A Publication of the Canadian Society for Pharmaceutical Sciences, doi:10.18433/jpps31457

Poopalasingam, Korenkov, Ashurov, Strobel, Fish et al., Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes and New Infections, doi:10.2139/ssrn.4000128

Schwartz, Does Ivermectin have a place in the treatment of mild Covid-19? New Microbes and New Infections

Schwartz, Does ivermectin have a place in the treatment of mild Covid-19?, New Microbes and New Infections, doi:10.1016/j.nmni.2022.100985

Siedner, Tay, Myf, Fraser, Chan et al., Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Open Forum Infectious Diseases, doi:10.1093/ofid/ofab318

Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/BJ20120150

Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648

Wölfel, Corman, Guggemos, Seilmaier, Zange et al., Virological assessment of hospitalized patients with COVID-2019, Nature, doi:10.1038/s41586-020-2196-x

Zaidi, Dehgani-Mobaraki, The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review, J Antibiot, doi:10.1038/s41429-021-00491-6

Zein, Sulistiyana, Raffaelo, Pranata, Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials, Diabetes Metab Syndr n.d, doi:10.1016/j.dsx.2021.102186

Zhang, Song, Ci, Ju, Li, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, doi:10.1007/s00011-008-8007-8

{ 'indexed': {'date-parts': [[2022, 7, 8]], 'date-time': '2022-07-08T06:43:46Z', 'timestamp': 1657262626366}, 'reference-count': 0, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 7, 1]], 'date-time': '2022-07-01T00:00:00Z', 'timestamp': 1656633600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 7, 3]], 'date-time': '2022-07-03T00:00:00Z', 'timestamp': 1656806400000}, 'content-version': 'vor', 'delay-in-days': 2, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 7]]}, 'DOI': '10.1016/j.ijid.2022.07.003', 'type': 'journal-article', 'created': {'date-parts': [[2022, 7, 8]], 'date-time': '2022-07-08T06:07:31Z', 'timestamp': 1657260451000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The effect of ivermectin on the viral load and culture viability in early treatment of ' 'non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled ' 'trial', 'prefix': '10.1016', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6007-0383', 'authenticated-orcid': False, 'given': 'Asaf', 'family': 'Biber', 'sequence': 'first', 'affiliation': []}, {'given': 'Geva', 'family': 'Harmelin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dana', 'family': 'Lev', 'sequence': 'additional', 'affiliation': []}, {'given': 'Li', 'family': 'Ram', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-2899-1665', 'authenticated-orcid': False, 'given': 'Amit', 'family': 'Shaham', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ital', 'family': 'Nemet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Limor', 'family': 'Kliker', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-4839-8997', 'authenticated-orcid': False, 'given': 'Oran', 'family': 'Erster', 'sequence': 'additional', 'affiliation': []}, {'given': 'Michal', 'family': 'Mandelboim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eli', 'family': 'Schwartz', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'container-title': 'International Journal of Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S120197122200399X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S120197122200399X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 7, 8]], 'date-time': '2022-07-08T06:07:32Z', 'timestamp': 1657260452000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S120197122200399X'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 7]]}, 'references-count': 0, 'alternative-id': ['S120197122200399X'], 'URL': 'http://dx.doi.org/10.1016/j.ijid.2022.07.003', 'relation': {}, 'ISSN': ['1201-9712'], 'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'International Journal of Infectious Diseases', 'published': {'date-parts': [[2022, 7]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0